Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q3 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $175.8 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.